Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Repligen Analyst Ratings
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205
Repligen (NASDAQ:RGEN) Shareholder Returns Have Been Favorable, Earning 93% in 5 Years
Craig-Hallum Maintains Repligen(RGEN.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $Repligen(RGEN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.4% and a total average return of -4.2% over the past
Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA) and Repligen (RGEN)
Repligen Financial Statements Require Restatement Due to Revenue Recognition Error
After-hours Movers: Steelcase, Hess Midstream Partners, Repligen
Express News | Repligen: Reaffirming Prior 2024 Rev Guidance; Understated $6.6 Mln in H1 2024 to Be Added Incrementally, Thus Updating FY Range to $627 Mln-$642 Mln
Express News | Repligen Corp -Does Not Anticipate Restatement Will Have Any Impact on Co’s Overall Business Ops, Previously Reported Strategic Outlook
Express News | Repligen Corp -Consolidated Financial Statements for Qtr Ended March 31, 2023 Through June 30, for Year Ended Dec 31, 2023 Require Restatement
Express News | Repligen Corp : RBC Raises Target Price to $205 From $190
Repligen(RGEN.US) Director Sells US$3.23 Million in Common Stock
$Repligen(RGEN.US)$ Director Hunt Anthony sold 22,191 shares of common stock on Sep 10, 2024 at an average price of $145.37 for a total value of $3.23 million.Source: Announcement What is statement
Goldman's 'Goldilocks' Mid-cap Picks That Trade at Reasonable Valuations
Form 144 | Repligen(RGEN.US) Officer Proposes to Sell 3.21 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 10, $Repligen(RGEN.US)$ Officer Hunt Anthony intends to sell 22,191 shares of its common stock on Sep 10, with a total market value of approximately $3.21 million.
50 Stocks That May See Selling Pressure as Investors Begin Looking to Book Tax Losses
S&P 500 Futures Climb In Premarket Trading; Summit Therapeutics, Palantir Technologies Lead
Wells Fargo Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Wells Fargo analyst Brandon Couillard maintains $Repligen(RGEN.US)$ with a buy rating, and maintains the target price at $180.According to TipRanks data, the analyst has a success rate of 63.8% and